191 related articles for article (PubMed ID: 27764790)
41. Effect of molecular targeted agents in chemotherapy for treating platinum-resistant recurrent ovarian cancer: A systematic review and meta-analysis.
Liu L; Xiong W
Medicine (Baltimore); 2021 Aug; 100(32):e26849. PubMed ID: 34397893
[TBL] [Abstract][Full Text] [Related]
42. Kallikrein expression as a prognostic factor in ovarian cancer: a systematic review and meta-analysis.
Wu Y; Lu M; Zhou Q
J BUON; 2015; 20(3):855-61. PubMed ID: 26214640
[TBL] [Abstract][Full Text] [Related]
43. Prognostic role of USP7 expression in cancer patients: A systematic review and meta-analysis.
Kisaï K; Koji S
Pathol Res Pract; 2021 Nov; 227():153621. PubMed ID: 34562828
[TBL] [Abstract][Full Text] [Related]
44. From targeted therapy in ovarian cancer to personalizing therapy for ovarian cancer.
Gómez-Raposo C; Mendiola M; Barriuso J; Hardisson D; Redondo A
Expert Opin Investig Drugs; 2011 May; 20(5):591-4. PubMed ID: 21452927
[TBL] [Abstract][Full Text] [Related]
45. Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis.
Schwaederle M; Zhao M; Lee JJ; Lazar V; Leyland-Jones B; Schilsky RL; Mendelsohn J; Kurzrock R
JAMA Oncol; 2016 Nov; 2(11):1452-1459. PubMed ID: 27273579
[TBL] [Abstract][Full Text] [Related]
46. Altered long noncoding RNAs and survival outcomes in ovarian cancer: A systematic review and meta-analysis (PRISMA Compliant).
Ning L; Hu YC; Wang S; Lang JH
Medicine (Baltimore); 2018 Aug; 97(32):e11481. PubMed ID: 30095613
[TBL] [Abstract][Full Text] [Related]
47. Does the age affect the efficacy of angiogenesis inhibitors in ovarian cancer? A meta-analysis of randomized controlled trials.
Miao H; Miao CX; Han J; Li N
Eur Rev Med Pharmacol Sci; 2017 Jul; 21(13):3047-3053. PubMed ID: 28742202
[TBL] [Abstract][Full Text] [Related]
48. Retrospective analysis of survival improvement by molecular biomarker-based personalized chemotherapy for recurrent ovarian cancer.
Kim Y; Guntupalli SR; Lee SJ; Behbakht K; Theodorescu D; Lee JK; Diamond JR
PLoS One; 2014; 9(2):e86532. PubMed ID: 24505259
[TBL] [Abstract][Full Text] [Related]
49. Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval.
Jardim DL; Schwaederle M; Wei C; Lee JJ; Hong DS; Eggermont AM; Schilsky RL; Mendelsohn J; Lazar V; Kurzrock R
J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26378224
[TBL] [Abstract][Full Text] [Related]
50. New developments in molecular targeted therapy of ovarian cancer.
Guan LY; Lu Y
Discov Med; 2018 Nov; 26(144):219-229. PubMed ID: 30695681
[TBL] [Abstract][Full Text] [Related]
51. Genomic sequencing to inform therapy in advanced pancreatic cancer: A systematic review and meta-analysis of prospective studies.
Meti N; Kelly D; Allen MJ; Lanys A; Fazelzad R; Ramjeesingh R; Zogopoulos G; Notta F; Knox JJ; Amir E; Gallinger S; O'Kane G; Grant RC
Cancer Treat Rev; 2021 Dec; 101():102310. PubMed ID: 34757307
[TBL] [Abstract][Full Text] [Related]
52. Comparative efficacy of targeted maintenance therapy for newly diagnosed epithelial ovarian cancer: a network meta-analysis.
Xu X; Yin S; Guo H; Li M; Qian Z; Tian X; Li T
Cancer Manag Res; 2019; 11():4119-4128. PubMed ID: 31190984
[No Abstract] [Full Text] [Related]
53. Skeletal muscle mass as a prognostic indicator of outcomes in ovarian cancer: a systematic review and meta-analysis.
Rinninella E; Fagotti A; Cintoni M; Raoul P; Scaletta G; Scambia G; Gasbarrini A; Mele MC
Int J Gynecol Cancer; 2020 May; 30(5):654-663. PubMed ID: 32241875
[TBL] [Abstract][Full Text] [Related]
54. Targeted therapy clinical trials in ovarian cancer: improved outcomes by gene mutation screening.
Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S
Anticancer Drugs; 2020 Feb; 31(2):101-109. PubMed ID: 31743133
[TBL] [Abstract][Full Text] [Related]
55. No Effect of Metformin on Ovarian Cancer Survival: A Systematic Review and Meta-Analysis of Cohort Studies.
Wang Y; Liu X; Yan P; Bi Y; Liu Y; Zhang ZJ
Curr Pharm Des; 2019; 25(23):2595-2601. PubMed ID: 31333095
[TBL] [Abstract][Full Text] [Related]
56. Revisiting Risk and Benefit in Early Oncology Trials in the Era of Precision Medicine: A Systematic Review and Meta-Analysis of Phase I Trials of Targeted Single-Agent Anticancer Therapies.
Mackley MP; Fernandez NR; Fletcher B; Woolcott CG; Fernandez CV
JCO Precis Oncol; 2021 Nov; 5():17-26. PubMed ID: 34994588
[TBL] [Abstract][Full Text] [Related]
57. Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials.
Schwaederle M; Zhao M; Lee JJ; Eggermont AM; Schilsky RL; Mendelsohn J; Lazar V; Kurzrock R
J Clin Oncol; 2015 Nov; 33(32):3817-25. PubMed ID: 26304871
[TBL] [Abstract][Full Text] [Related]
58. Analysis of Efficacy-To-Safety Ratio of Angiogenesis-Inhibitors Based Therapies in Ovarian Cancer: A Systematic Review and Meta-Analysis.
Simion L; Rotaru V; Cirimbei C; Stefan DC; Gherghe M; Ionescu S; Tanase BC; Luca DC; Gales LN; Chitoran E
Diagnostics (Basel); 2023 Mar; 13(6):. PubMed ID: 36980348
[TBL] [Abstract][Full Text] [Related]
59. Microvascular Density as a Predictive Biomarker for Bevacizumab Survival Benefit in Ovarian Cancer: Back to First Principles?
Ferrara N
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059427
[No Abstract] [Full Text] [Related]
60. Targeting Six Hallmarks of Cancer in Ovarian Cancer Therapy.
Gong H; Nie D; Li Z
Curr Cancer Drug Targets; 2020; 20(11):853-867. PubMed ID: 32807056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
